anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a method of treating a hyperproliferative disease or other condition in an animal by first determining the performance status of the animal and then administering a vitamin D compound or mimic thereof to an animal determined to exhibit diminished performance status. Also disclosed is a method of treating a hyperproliferative disease or other condition in an animal by first detecting a biomarker of inflammation in the animal and then administering a vitamin D compound or mimic thereof to the animal determined to exhibit an elevated or diminished level of the biomarker. Also disclosed a method of improving delivery of a therapeutic agent to tumors or other tissues characterized by a reduced response to therapy. Also disclosed is a method of improving the perfusion of blood and oxygen to tumors or other tissues comprising administering a vitamin D compound or mimic thereof, thereby improving the oxygenation of the tumors or other tissues. Also disclosed is a method of treating an animal with tumors or other tissues characterized by impaired perfusion and/or hypoxia, comprising determining whether the tumor or other tissue exhibits impaired perfusion and/or hypoxia, administering to the animal a vitamin D compound or mimic thereof and a compound known to decrease inflammation in tumors or other tissues and administering to the tumors or other tissues one or more therapeutic agents or treatments. Also disclosed is a method for palliative care of terminal cancer patients by administering to the patient a vitamin D compound or mimic thereof. Also disclosed in a method for improving the perfusion, distribution and/or penetration of a therapeutic agent into a tumor microenvironment comprising administering a vitamin D compound or a mimic thereof by high dose pulse administration (HDPA).
The invention belongs to the technical field of aquaculture, and particularly relates to a medicament applicable to intervention shrimp ovary ripening and a preparation method as well as application thereof. The preparation method is characterized by comprising the following three steps of: extracting bletilla striata polysaccharide as a carrier; preparing bletilla striata polysaccharide sol of a shrimp blood lymph characteristic; and preparing a ripening intervention medicament. Experiments show that the brooding rate is not less than that of an eyestalk ablation group when the medicament is applied to red swamp crayfishes at the early stage of vitellogenesis under the same breeding condition. The death rate tends to be zero after the shrimps are treated for a week. Comparatively, the death rate for bilateral eyestalk ablation under the same condition in a week is 71.67 percent, and the death rate for a unilateral eyestalk ablation group under the same condition in a week is 57.5 percent. After the medicament is used for treating the red swamp crayfishs during vitellogenesis for 45 days, the brooding rate is 84.82 percent, the death rate in a week is only 1.67 percent, the stability is guaranteed and the death rate is obviously reduced, P is less than 0.01, and synchronous development and maturing of ovary are promoted. The medicament has a stable material source; and the method is simple and practical and has the prospect of being applied as an alternative method for an eyestalk ablation shrimp ovary ripening method.
A method for organizing software of a fluid management system is provided to facilitate management/update of a processor system of the fluid management system, which is a medical treatment device for performing outside blood treatment such as blood dialysis or filtration. The software comprises treatment software(22) for controlling and monitoring the medical treatment of a patient, and tool software(26) for controlling and monitoring service and/or generation activities. The treatment software is stored to the processor system(10) as the resident software and the tool software is stored to the processor system as the non-resident software. The non-resident software includes the software for updating the resident software. An external data storage device(40) is connected to the processor system and loads the non-resident software to the processor system. The processor system transmits information for the software and data stored in the external data storage device.
Participants will receive 1 preparation (Treatment F) of osivelotor pellet/granules on Day 1 which they will put in their mouth and swallow. They might have a dose on Day 7 which they will put in their mouth and then spit it out; afterwards they will complete the taste questionnaire.
INTRODUCTION: Achieving urinary continence is a key goal in children born with the bladder exstrophy-epispadias complex (BEEC). Unfortunately, this goal is only moderately achieved despite sometimes extensive surgical treatment. Undergoing repeated hospitalization and operations may consequently have a negative impact on quality of life. We therefore believe that other, conservative treatment options should be explored in an earlier stage of incontinence treatment in BEEC patients. As part of this, an intensive urotherapy program based on was offered to patients with persistent incontinence after reconstructive surgery for BEEC.
OBJECTIVE: The aim of this study is to evaluate the benefits of intensive urotherapy on incontinence after reconstructive surgery in children with BEEC.
STUDY DESIGN: A retrospective chart study was performed including all children who were enrolled in an intensive urotherapy program because of persistent incontinence after reconstructive surgery for BEEC. Urotherapy consisted of a ten-day inpatient training program based on cognitive behavioral therapy, with intensive follow-up by experienced urotherapists. Main outcome measurement was continence, expressed as the percentage of children that achieved complete continence (good result; 100% dry) or 50-99% decrease of wet days a week (improved result) after treatment.
RESULTS: Data of 33 patients with a mean age of 10.6 years were analyzed. In 61% of cases (20/33) an improved or good result was reported on incontinence after urotherapy. Children with classic bladder exstrophy more often achieved a good or improved result (13/16; 81%), compared to children with epispadias (6/16; 38%). The only patient with a cloacal exstrophy completed treatment with an improved result. From the group of patients with persistent incontinence, 75% (12/16) reported that the complaints were socially acceptable at the end of follow-up.
DISCUSSION: By following our intensive urotherapy program the majority of patients achieved complete continence or improved incontinence. In addition, our results show that the inpatient training program has a positive impact on acceptance in cases of persistent incontinence. The urotherapists offer individualized care and clear guidance, which we deem essential elements of successful treatment. Considering that repeated surgery may impede progress and offers no guarantee of continence, we recommend giving preference to conservative treatment options.
CONCLUSION: Our results show that 37% (12/33) of patients with BEEC who were enrolled in our intensive urotherapy program because of persistent incontinence after reconstructive surgery, achieved complete continence after urotherapy and 63% (21/33) still experienced some degree of incontinence. 75% of patients who did not achieve complete continence, described the remaining incontinence as socially acceptable. These findings strongly support counselling patients with BEEC to consider conservative treatment before opting for further surgery.
Patients receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).
The participants will be applied AMG and EMG on each arm of both arms when they finish routine monitoring before the induction of general anesthesia. After the participants being unconscious, we will find each participant's supramaximal current before injecting the neuromuscular blocking agents. During the operation, when the TOF count reaches 4 again and the height of T1 reaches 50% of baseline, we perform TOF tests using 4 currents (Supramaximal current, 0.7×supramaximal current, 0.5×supramaximal current, 0.3×supramaximal current), three times for respective current to figure out that low current can show the same level of TOF ratio as the supramaximal current. When the operation ends and the T1 reaches 100% of baseline, we perform TOF tests with 4 currents again. In the postanesthesia care unit, we use EMG only and perform TOF tests with 4 currents again. The participants can feel pain by the stimulants during the tests, so if they refuse the tests, we stop the tests and record it.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to therapeutic agents used in broncho-obstructive states. Invention relates to a method of preparing theophylline-base medicinal agent by its mixing with a composite polymeric carrier dry powder that presents an interpolymeric complex of polymethacrylic acid and polyethylene glycol. Then the prepared mixture is dried to value of residual moisture 1%, not above, granulated by screening through a sieve with the following powdering with calcium stearate and tableting. EFFECT: simplified method of agent preparing, increased stability of end product. 2 cl, 1 tbl
We have generated novel molecularly marked FMDV A 24 LL3D YR  and A 24 LL3B PVKV 3D YR  vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3D pol  and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A 24 LL3D YR . Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
The downy mildew of grapevine (Vitis vinifera L.) is caused by Plasmopara viticola and is a major production problem in most grape-growing regions. The vast majority of effectors act as virulence factors and sabotage plant immunity. Here, we describe in detail one of the putative P. viticola Crinkler (CRN) effector genes, PvCRN11, which is highly transcribed during the infection stages in the downy mildew-susceptible grapevine V. vinifera cv. 'Pinot Noir' and V. vinifera cv. 'Thompson Seedless'. Cell death-inducing activity analyses reveal that PvCRN11 was able to induce spot cell death in the leaves of Nicotiana benthamiana but did not induce cell death in the leaves of the downy mildew-resistant V. riparia accession 'Beaumont' or of the downy mildew-susceptible 'Thompson Seedless'. Unexpectedly, stable expression of PvCRN11 inhibited the colonization of P. viticola in grapevine and Phytophthora capsici in Arabidopsis. Both transgenic grapevine and Arabidopsis constitutively expressing PvCRN11 promoted plant immunity. PvCRN11 is localized in the nucleus and cytoplasm, whereas PvCRN11-induced plant immunity is nucleus-independent. The purified protein PvCRN11Opt initiated significant plant immunity extracellularly, leading to enhanced accumulations of reactive oxygen species, activation of MAPK and up-regulation of the defense-related genes PR1 and PR2. Furthermore, PvCRN11Opt induces BAK1-dependent immunity in the apoplast, whereas PvCRN11 overexpression in intracellular induces BAK1-independent immunity. In conclusion, the PvCRN11 protein triggers resistance against P. viticola in grapevine, suggesting a potential for the use of PvCRN11 in grape production as a protectant against downy mildew.
Patients randomized to home removal will be assigned to remove their catheters on postoperative day (POD) 2 (or if Th/F surgery, POD 4 or POD 3, respectively). They will be handed an instructional packed with visual, written and video instructions for catheter removal.
This prospective, multi-center study aims to determine the pharmacokinetics and pharmacodynamics of extended-infusion cefepime in CRRT. Patients on CRRT who are being initiated on cefepime 2000 mg IV every eight hours with a four-hour infusion will be considered for enrollment. Pre- and post-membrane serum levels will be drawn at scheduled intervals for both the first dose and again during another dose at steady state. Concomitant effluent and urine levels will also be obtained. A pharmacokinetic analysis will be performed and Monte Carlo simulations will be used to determine the probability of target attainment for various pharmacodynamic endpoints. Documented organism MICs will be used to determine the cumulative fraction of response.
NEW MATERIAL:A hydroxamic acid derivative of formula I (R is H, one, two or three 1-3C alkyloxy, phenyl, trihalomethyl or halogen groups). EXAMPLE:N-Hydroxy-N-(1-hydroxy-2-naphthyl)nenzamide. USE:The derivative exhibits an activity to inhibit 5-lipoxygenase or a mixture of the 5-lipoxygenase and 12-lipoxygenase and is useful for treating and preventing, e.g. allergic diseases such as bronchial asthma, nasal allergy, allergic ophthalmia and atopic dermatitis, circulatory diseases such as edema, ischemic diseases, hypertension and ischemic encephalopathia, psoriasis and viral diseases. PREPARATION:The compound of formula I is prepared e.g. by the reaction equation.
BACKGROUND: There are insufficient data and measuring tools for parental perception of defecation and constipation in Thai children. The primary objective of this study was to develop a tool to measure parental perceptions towards defecation and constipation in children. The secondary objective was to identify parental understanding and misconceptions about these issues.
METHODS: The authors developed a questionnaire in three domains: knowledge, attitude, and practice. Content validity was evaluated using the item-objective congruence index (IOC) by five experts. The reliability of the measure was assessed based on both internal consistency and test-retest reliability. Then, a descriptive cross-sectional survey was conducted on Thai parents at pediatric outpatient clinics and wards in Bhumibol Adulyadej Hospital.
RESULTS: The authors developed a first draft questionnaire consisting of 31 items, which were categorized into three domains of knowledge, attitude, and practice. During expert validation, five items were disqualified. To assess the questionnaire's reliability, Cronbach's alpha value was calculated and found to be 0.229 for the original questionnaire. However, after removing irrelevant questions, Cronbach's alpha value increased to 0.511 for an 18-item questionnaire. The adjusted questionnaire demonstrated excellent test-retest reliability (Intraclass correlation coefficient, ICC = 0.91). The survey with 306 parents revealed parental misconceptions about the pathophysiology of stool withholding, stool soiling indicating constipation, toilet training after meals, and monitoring bowel movements.
CONCLUSION: The developed questionnaire helps to assess parental perception regarding defecation and constipation in Thai children. Based on the survey results, the authors suggest that parental education on these issues is still necessary.
Dicyclomine hydrochloride is an antispasmodic and anticholinergic (antimuscarinic) agent available in the following form: 

Each capsule, for oral administration, contains 10 mg of dicyclomine hydrochloride. Each capsule also contains the following inactive ingredients: Corn Starch, Lactose Monohydrate, Magnesium Stearate, and Microcrystalline Cellulose. Capsule shells contain FD&C Blue No. 1, FD&C Red No. 4, and Gelatin. The imprinting ink contains Titanium Dioxide. 

Chemically, dicyclomine hydrochloride is [bicyclohexyl]-1-carboxylic acid, 2-(diethylamino) ethyl ester, hydrochloride with the structural formula: 

Dicyclomine hydrochloride occurs as a fine, white, crystalline, practically odorless powder with a bitter taste. It is soluble in water, freely soluble in alcohol and chloroform, and very slightly soluble in ether.
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in children. Like adults, children can develop the progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), which is characterized by hepatic inflammation, often in the presence of fibrosis. Children with NAFLD are at higher risk of liver-related complications, metabolic dysfunction, and cardiovascular disease in adulthood. Many factors contribute to the escalating prevalence of NAFLD in the pediatric population, among which are an array of dietary patterns such as overnutrition, poor diet quality, and heavy consumption of fat and sugar, including fructose. Findings from an increasing number of epidemiological studies support a connection between high habitual sugar consumption and NAFLD, especially within the context of obesity, but these studies are not able to demonstrate whether sugar is a contributing factor or instead an indicator of an overall poor diet (or lifestyle) quality. To date, only four randomized controlled dietary interventions assessing the effects of sucrose/fructose restriction on hepatic fat fraction in youth with obesity have been published. The objectives of this review are to summarize the key findings from these dietary interventions to achieve a better understanding of the strength of the relationship between dietary sugar restriction and liver fat reduction, despite their inherent limitations, and to discuss the potential impact of weight loss and fat mass reduction on improvement in hepatic steatosis.
1. The use of hydrophilic solvent-extract of mushroom as an effective component for prophylactic or a remedy for renal diseases. 2. The use of hydrophilic solvent-extract of mushroom as an effective component for prophylactic or a remedy for prophylactic or a remedy for progressive renal failure in undialyzed patients suffering from end-stage renal disease. 3. The use of hydrophilic solvent-extract of mushroom as an effective component of food for preventing or treating renal diseases. 4. The use of hydrophilic solvent-extract of mushroom as an effective component of food for prophylactic or a remedy for progressive renal failure in undialyzed patients suffering from end-stage renal disease. 5. The use of hydrophilic solvent-extract of mushroom as an effective component of food for effect of improving renal functions.
Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
BACKGROUND: Patients with hereditary antithrombin deficiency (HAD) have an increased risk of venous thromboembolism (VTE). The American Thrombosis and Hemostasis Network (ATHN) 12: HAD Pilot Project established a registry to collect data on patients with HAD.
OBJECTIVES: To inform current practice and serve as a platform to design a multicenter global registry for patients with HAD.
METHODS: The HAD registry was designed in 2020 to identify 100 patients with HAD receiving care at ATHN-affiliated centers. Demographics, type of HAD, thrombotic events, risk factors, anticoagulants, and antithrombin (AT) concentrate administration were recorded.
RESULTS: Ninety-four patients were included; 65% were females; 51% had type 1 HAD. Mean age at diagnosis was 26 years (SD, 18 years); 61% had VTE: 55% deep vein thrombosis and 27% pulmonary embolisms. Eight patients had arterial thrombosis. Recurrent thrombosis occurred in 58.6% of patients (44.8%) despite anticoagulation. The main risk factor for thrombosis in females was estrogen. Direct oral anticoagulants were prescribed in 30%, heparin in 34%, and warfarin in 32%. There were 139 pregnancies. Low-molecular-weight heparin was administered in 33% and AT concentrate in 19% and 11% prior to and after delivery, respectively. Twelve patients developed thrombosis in pregnancy. Seventy-nine patients underwent 239 surgeries or procedures, mainly gastrointestinal and vascular. Overall, 35% of participants received AT concentrate without adverse events.
CONCLUSION: In ATHN 12, VTE was the predominant manifestation, frequently recurrent. There was a trend toward using direct oral anticoagulants. Low-molecular-weight heparin was administered in one-third of pregnancies and AT concentrate in one-fifth without adverse events. These data should encourage prospective studies to optimize the management of these patients.
The invention comprises 1,4-dicaffeylquinic acid of the formula <FORM:0802669/IV (b)/1> and a process for its isolation from a decoction liquor containing it (preferably obtained from leaves of cardoon, Cynara cardunculus, or artichoke, Cynara scolymus) by treating the liquor with an excess of a water-soluble salt of barium or lead, respectively in the cold or with heating, and freeing the resulting separated precipitate, which contains the barium or lead salt of 1,4-dicaffeylquinic acid, from impurities by selective separation under acid conditions.  Three methods for the selective separation are described: (a) fractional elution of precipitated lead salts with 30-50 per cent acetic acid at 60-80 DEG  C., the active substance being recovered from the acid solution thus obtained by removal of lead with sulphuric acid and H2S, and concentration of the remaining liquid; (b) total dissolution of the barium or lead salt in a very slight excess of 10 per cent nitric acid, followed by fractional crystallization; (c) dissolution of the accompanying impurities in a slight excess of dilute sulphuric acid and then extraction of 1,4-dicaffeylquinic acid from the insoluble residue with an organic solvent, e.g. methanol, ethanol or dioxane.  The crude caffeylquinic acid obtained by the above methods is further purified by crystallization from dilute acetic acid or water.  In examples: (1) carbon leaves are boiled with water, the hot liquor treated with excess lead acetate solution, the precipitate separated by filtration or centrifugation and 1,4-dicaffeylquinic acid isolated by method (a) above; (2) artichloke leaves are boiled with water, filtered, the decoction concentrated under reduced pressure and treated with barium nitrate and barium hydroxide, yielding a yellow precipitate which is treated by method (c), extracting dicaffeylquinic acid with alcohol; (3) the yellow precipitate obtained as in (2) is treated with dilute nitric acid and allowed to stand, when the quinic acid crystallizes; (4) the precipitate obtained by treating a decoction of cardoon or artichoke leaves with lead acetate solution is treated by method (c), using ethanol as the organic solvent.  The structure of 1,4-dicaffeylquinic acid is confirmed (a) by acetylation to a hexa-acetate, which on hydrogenation gives a tetrahydro derivative; (b) by alkaline fusion to 3,4-dihydroxybenzoic acid; (c) saponification of the substance and of its tetrahydro derivative giving quinic acid together with 3,4-dihydroxy cinnamic acid or b -(3,4-dihydroxyphenyl) propionic acid respectively; and (d) by methylation to 1,4 - di - (31,41 - dimethoxycinnamoyl) quinic acid methyl ester.  Specification 802,668 is referred to.